An Investigation into the Opportunities and Challenges of Orphan Drug Regulations for Rare Diseases: A Comparative Policy and Evidence Synthesis

Abstract

The analysis shows that orphan drug frameworks have substantially reshaped the pharmaceutical innovation landscape, delivering concrete opportunities: Incentive-driven R&D growth: Orphan incentives have clearly stimulated discovery and development in areas previously neglected. Pipeline data reveal an exponential increase in rare disease trials, particularly for genetic and ultra-rare conditions. These incentives have catalyzed the rise of biotech SMEs, which rely heavily on exclusivity protections and grant support to de-risk investment. Adaptive and expedited pathways: Regulatory innovations such as the U.S. Accelerated Approval, EU PRIME, and Japan’s Sakigake designation have been effective in enabling earlier patient access. Crucially, these pathways can balance speed with responsibility when tied to robust post-marketing authorization (PMA) obligations, ensuring that uncertainty is progressively reduced. Infrastructure dividends: Investments in registries, natural history databases, and networks of centers of excellence have created public goods. These infrastructures not only enhance trial feasibility but also underpin real-world learning systems, contributing to better long-term outcome measurement and fostering international collaboration.